Comparison of Two Different Doses of Bemiparin in COVID-19

• Status: Recruiting
• Trial end date: 2021-07-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients requiring hospitalization due to COVID-19 pneumonia (non-severe) will be randomized to standard prophylactic doses or full therapeutic dose of bemiparin (a LMWH) for 10 days.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
• Treatments: Bemiparin

Criteria

Inclusion Criteria:

• Age (equal or more than 18 yo)

• Hospitalization at conventional wards due to COVID-19 related mild or moderate pneumonia (CURB65<3 points; Sat. O2>90%)

• 3-4 points according to the WHO ordinal scale.

• Confirmed COVID-19 (PCR or other validated test)

• D-dimer >500 ng/mL

• Sign of informed consent

• The patient is able, according to investigator's opinion, to deal with all the requirements of the clinical trial.

Exclusion Criteria: